Results 11 to 20 of about 18,044 (238)

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick, Curtis, Jeffrey R, Evans, Michael, He, Zeling, Huang, Jie, Johansson, Tracy, Liao, Katherine P, Michaud, Kaleb, Schmajuk, Gabriela   +8 more
core   +1 more source

Biosimilars [PDF]

Therapeutische Umschau, 2011
Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire   +6 more sources

Potential Cost-Savings From the Use of the Biosimilars in Slovakia

Frontiers in Public Health, 2020
Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate the potential cost-savings from the use of biosimilars in Slovakia based on two different data sources.Methods: National reimbursement lists from the Czech Republic ...
Tomas Tesar, Peter Golias, Zuzana Kobliskova, Martin Wawruch, Paweł Kawalec, András Inotai, András Inotai   +6 more
doaj   +1 more source

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

Pharmaceuticals, 2021
Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
Manuel García-Goñi, Isabel Río-Álvarez, David Carcedo, Alba Villacampa   +3 more
doaj   +1 more source

Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption

Medicina, 2022
(1) Background: A biosimilar is a biologic medical product that has been approved by the United States Food and Federal Drug Administration (FDA) and is an almost identical copy of an original biologic product yet manufactured by a different company ...
John Hair, Thomas Maryon, Cristian Lieneck   +2 more
doaj   +1 more source

Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective [PDF]

Global Journal on Quality and Safety in Healthcare, 2020
Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients.
Mansoor A. Khan, Mohammed A. Aseeri, Majed A. Alshamrani, Abdelmajid H. Alnatsheh, Hani S. Alhamdan   +4 more
doaj   +1 more source

T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia

Blood Advances, 2017
: Immunogenicity of biotherapeutics and the elicitation of anti-drug antibodies are a key concern for their efficacy, pharmacokinetics, and safety.
Tina Rubic-Schneider, Masataka Kuwana, Brigitte Christen, Manuela Aßenmacher, Otmar Hainzl, Frank Zimmermann, Robert Fischer, Vera Koppenburg, Salah-Dine Chibout, Timothy M. Wright, Andreas Seidl, Michael Kammüller   +11 more
doaj   +1 more source

Physicians’ perceptions of the uptake of biosimilars: a systematic review

BMJ Open, 2020
Objectives To examine physicians’ perceptions of the uptake of biosimilars.Design Systematic review.Data sources MedLine Ovid and Scopus databases at the end of 2018.Eligibility criteria Original scientific studies written in English that addressed ...
Katri Hämeen-Anttila, Kati Sarnola, Merja Merikoski, Johanna Jyrkkä   +3 more
doaj   +1 more source

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2019
Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).
Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan   +7 more
doaj   +1 more source

Pharmacovigilance of Biosimilars [PDF]

, 2013
In lieu of an abstract, here is the article\u27s first paragraph: Biotech industry forms the backbone of the current pharmaceutical products. Seven out of top ten anticipated drugs of the industry in 2014 will be biologics [1].
Chablani, Lipika
core   +2 more sources